M3
6 drugs Respiratory
2
approved indications
6
Approved Drugs
5
Companies
4
Indications
1
Therapeutic Areas
Top Drugs
Unlock Full Target Intelligence PRO
✓ Competitive landscape by company (5 companies)
✓ All 6 approved drugs
✓ Therapeutic area breakdown
✓ Full indication list (4 indications)
✓ Patent cliff analysis
✓ Clinical trials pipeline
Upgrade to Pro
Starting at $99/mo
Drugs by Company
COVIS 2 drugs
ALEMBIC 1 drug
Boehringer Ingelheim 1 drug
By Therapeutic Area
Respiratory 5 drugs
Other 1 drugs
Drugs by Company PRO
COVIS 2 drugs
ALEMBIC 1 drug
Boehringer Ingelheim 1 drug
GSK 1 drug
Viatris 1 drug
By Therapeutic Area
Respiratory 5 drugs
SPIRIVA RESPIMAT, INCRUSE ELLIPTA, DUAKLIR PRESSAIR, TUDORZA PRESSAIR +1 more
Other 1 drugs
DARIFENACIN HYDROBROMIDE
Indications Treated
Chronic Obstructive Pulmonary DiseaseOveractive BladderUrge Urinary IncontinenceAsthma
All Drugs Targeting M3
| Drug | Company | Approved | Indications | Therapeutic Area |
|---|---|---|---|---|
| DARIFENACIN HYDROBROMIDE | ALEMBIC | 2015 | 2 | |
| SPIRIVA RESPIMAT | Boehringer Ingelheim | 2014 | 2 | Respiratory |
| INCRUSE ELLIPTA | GSK | 2014 | 1 | Respiratory |
| DUAKLIR PRESSAIR | COVIS | 2019 | 1 | Respiratory |
| TUDORZA PRESSAIR | COVIS | 2012 | 1 | Respiratory |
| YUPELRI | Viatris | 2018 | 1 | Respiratory |